Table 2 Seropositivity rates for NMO-IgG and AQP4 autoantibodies in different groups of central nervous system idiopathic inflammatory demyelinating disorders, other neurological disorders, and healthy subjects.
Patient/control groups | Number of subjects | Number seropositive for NMO-IgG by tissue-based IIFA (%) | Number seropositive for AQP4 autoantibody by cell-based IIFA (%) | Significance p value |
|---|---|---|---|---|
NMO | 18 | 11 (61%) | 14 (78%) [3 +++, 3 ++, 8 +] | ns |
Relapsing myelitis | 15 | 6 (40%) | 9 (60%) [4 ++, 5 +] | ns |
Relapsing myelitis with LETM | 12 | 6 (50%) | 9 (75%) [4 ++, 5 +] | ns |
Single attack of acute myelitis | 25 | 0 | 1 (4%) [+] | ns |
Single attack of LETM | 2 | 0 | 1 [+] | ns |
Relapsing ON | 9 | 2 (22%) | 3 (33%) [2 ++, 1 +] | ns |
Single attack of ON | 14 | 1 (7%) | 2 (14%) [1 ++, 1 +] | ns |
Classical MS | 40 | 0 | 0 | ns |
ADEM | 7 | 0 | 0 | ns |
Healthy subjects | 10 | 0 | 0 | ns |
Other neurological disorders | 35 | 0 | 0 | ns |